Group 1 - The core viewpoint of the article is that WuXi AppTec (603259.SH/02359) has announced a significant increase in its revenue forecast for the year 2025, projecting approximately 45.456 billion yuan, marking a historical high [1] - The company has raised its annual performance guidance for the second time in the third quarter, indicating a strong focus on customer demand, business model, and management execution certainty [1] - WuXi AppTec expects its continuous operating business to return to double-digit growth, with an adjusted growth rate of 17-18%, and overall revenue revised to 43.5-44 billion yuan [1] Group 2 - In terms of profitability, key indicators under three metrics are expected to grow at a rate higher than revenue, with adjusted non-IFRS net profit, net profit attributable to shareholders, and net profit attributable to shareholders after deducting non-recurring gains and losses projected to increase by approximately 41.33%, 102.65%, and 32.56% year-on-year, respectively [1]

Core Viewpoint - WuXi AppTec has reported record-high revenue and profit figures for the fiscal year 2025, with basic earnings per share doubling to 6.70 CNY per share [1] Group 1: Financial Performance - The company achieved historical highs in revenue and profit across three metrics for the fiscal year 2025 [1] - The expected net profit attributable to shareholders for 2025 is projected to lead to a record cash dividend of over 5.7 billion CNY [1] Group 2: Shareholder Returns - WuXi AppTec has maintained a leading cash dividend ratio of 30% since its listing, reflecting its commitment to returning value to shareholders [1] - The anticipated rapid growth in net profit will be shared with shareholders through cash dividends [1] Group 3: Incentive Plans - The company has met the core unlocking conditions for its 2025 H-share incentive trust plan, with revenue targets set at 42 billion CNY and 43 billion CNY for additional stock grants [1] - A total of 2.5 billion HKD in equity incentives is set to be unlocked, aimed at fostering long-term development with core talent [1]

Core Viewpoint - WuXi AppTec has announced a significant increase in both revenue and profit for the fiscal year 2025, indicating strong operational performance and growth potential [1] Financial Performance - The company expects total revenue of approximately 45.456 billion yuan, representing a year-on-year growth of 15.84% [1] - Revenue from continuing operations is projected to grow by 21.4%, showcasing robust development in its core business [1] - Key profit indicators have also seen substantial year-on-year increases, with adjusted non-IFRS net profit, net profit attributable to shareholders, and net profit after deducting non-recurring items growing by 41.33%, 102.65%, and 32.56% respectively [1] - Overall, WuXi AppTec's revenue and three major profit metrics are set to surpass historical peaks, highlighting a trend of high-quality growth [1]

北京商报讯（记者 王寅浩 宋雨盈）1月12日，药明康德发布2025年度业绩预增公告，公司预计2025年实 现营业收入约454.56亿元，同比增长约15.84%；实现经调整归母净利润约149.57亿元，同比增长约 41.33%；实现归属于公司股东的净利润约191.51亿元，同比增长约102.65%。 ...

附："2025中国企业ESG百强"榜 新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点 击查看【 ESG评级中心服务手册】 在全球可持续发展浪潮席卷而来的当下，ESG（环境、社会、公司治理）已成为衡量企业高质量发展的核心标尺，更是连接企业价值与社会价值的关键纽 带。随着国内ESG生态体系的加速完善，政策监管持续收紧、资本市场对ESG表现的关注度不断飙升，企业的可持续发展能力愈发成为其核心竞争力的重 要组成部分。 在此行业背景下，新浪财经重磅发布"2025中国企业ESG百强"榜单。该榜单依托新浪财经专业的ESG评级体系，以5000余家A股上市公司及在港上市内地 企业为评价对象，创新性搭建18套行业ESG评价模型，纳入150余项ESG指标，通过量化模型综合演算，对企业ESG表现进行全面、客观的综合评价，最 终筛选出中国ESG实践的标杆企业。榜单不仅为行业树立了发展典范，更为投资者提供了极具参考价值的决策依据。 药明康德在环境、社会、公司治理领域开展了大量工作，积累了丰富的创新实践与扎实的落地成果。凭借在ESG各领域的卓越表现，药 ...

Core Viewpoint - WuXi AppTec (603259.SH) expects to achieve a net profit attributable to shareholders of approximately RMB 19.151 billion in 2025, representing a year-on-year growth of about 102.65% [1] Group 1: Business Model and Strategy - The company continues to focus on its unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing Organization) business model [1] - WuXi AppTec is committed to meeting customer demands for empowerment and is continuously expanding new capabilities and building new production capacity [1] - The company is dedicated to optimizing production processes and improving operational efficiency to drive steady business growth [1] Group 2: Commitment to Clients and Market Impact - WuXi AppTec aims to empower clients effectively and is committed to bringing more new and effective drugs to global patients [1]

Core Viewpoint - WuXi AppTec (603259.SH) expects to achieve a net profit attributable to shareholders of approximately RMB 19.151 billion in 2025, representing a year-on-year growth of about 102.65% [1] Group 1: Business Model and Strategy - The company continues to focus on its unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing Organization) business model [1] - It is committed to meeting customer demands for empowerment and is continuously expanding new capabilities and building new production capacity [1] - The company aims to optimize production processes and improve operational efficiency to drive steady business growth [1] Group 2: Commitment to Clients and Market - WuXi AppTec is dedicated to empowering clients efficiently and aims to bring more new and effective drugs to patients worldwide [1]

Group 1 - The company expects a revenue increase of approximately 15.84% for the fiscal year ending December 31, 2025, with projected revenue of about RMB 45,456.17 million [1] - The adjusted net profit attributable to shareholders is anticipated to be around RMB 14.957 billion, reflecting a year-on-year growth of approximately 41.33% [1] - The net profit attributable to shareholders is projected to reach approximately RMB 19.151 billion, representing a significant year-on-year increase of about 102.65% [1] Group 2 - The company continues to focus on its unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing) business model, enhancing capabilities and optimizing production processes to drive steady growth [2] - Non-recurring profit items impacting net profit include expected net gains of approximately RMB 4.161 billion from the sale of part of its stake in WuXi XDC Cayman Inc. and about RMB 1.434 billion from the sale of 100% stakes in two clinical research companies [2]

Core Viewpoint - WuXi AppTec (02359.HK) expects to achieve a revenue of approximately RMB 45.456 billion for the fiscal year ending December 31, 2025, representing a year-on-year growth of about 15.84% [1] Financial Performance - The revenue from continuing operations is expected to grow by approximately 21.40% year-on-year [1] - The adjusted net profit attributable to shareholders is projected to be around RMB 14.957 billion, reflecting a year-on-year increase of approximately 41.33% [1] - The net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to be about RMB 13.241 billion, with a year-on-year growth of approximately 32.56% [1] - The total net profit attributable to shareholders is anticipated to reach approximately RMB 19.151 billion, indicating a year-on-year increase of about 102.65% [1] - The basic earnings per share are expected to be around RMB 6.70, representing a year-on-year growth of approximately 104.27% [1] Business Strategy - The company continues to focus on its unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing) business model [1] - WuXi AppTec aims to meet customer demands for empowerment, continuously expanding new capabilities and building new production capacity [1] - The company is committed to optimizing production processes and improving operational efficiency to drive steady business growth and effectively empower clients [1] Non-Recurring Gains - The impact of non-recurring gains on net profit attributable to shareholders primarily comes from the net gain from the sale of part of its stake in WuXi XDC Cayman Inc., estimated at approximately RMB 4.161 billion [2] - Additionally, the net gain from the sale of 100% equity in Shanghai Kangde Hongyi Medical Clinical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd. is expected to be around RMB 1.434 billion [2]

证券代码：603259 证券简称：药明康德 公告编号：临 2026-002 无锡药明康德新药开发股份有限公司 2025 年度业绩预增公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 无锡药明康德新药开发股份有限公司（以下简称"本公司"或"公司"）持 续聚焦独特的"一体化、端到端"CRDMO（合同研究、开发与生产）业务模式， 紧抓客户对赋能需求的确定性，不断拓展新能力、建设新产能，持续优化生产工 艺和提高经营效率，推动业务持续稳健增长，高效极致赋能客户并致力于将更多 新药、好药带给全球病患。 1、公司预计 2025 年度（以下简称"本期"）实现营业收入约人民币 4,545,617 万元，同比增长约 15.84%，其中持续经营业务收入同比增长约 21.40%。 2、公司预计本期实现经调整非《国际财务报告准则》下归属于本公司股东 的净利润（以下简称"经调整归母净利润"）约人民币 1,495,655 万元，同比增 长约 41.33%。 3、公司预计本期实现归属于本公司股东的扣除非经常性损益的净利润约人 民币 1,3 ...